- |||||||||| everolimus / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Treatment of Patients With RAD001 With Progressive Sarcoma (clinicaltrials.gov) - Oct 5, 2017 P2, N=71, Completed, Recruiting --> Completed | N=30 --> 6 | Trial primary completion date: Jul 2019 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2017
- |||||||||| Journal: NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency. (Pubmed Central) - Oct 5, 2017
Upon BX795 or TBK1 siRNA treatment, NLRX1 depletion exhibited less inhibitory effects on reactivation and infectious virion production, suggesting that NLRX1 facilitates KSHV lytic replication by negatively regulating IFNβ responses. Our data suggests that NLRX1 plays a positive role in KSHV lytic replication by suppressing the IFNβ response during the process of KSHV reactivation, which might serve as a potential target for restricting KSHV replication and transmission.
- |||||||||| Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial primary completion date, IO biomarker: Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 3, 2017 P=N/A, N=12, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Mar 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- |||||||||| Ibrance (palbociclib) / Pfizer, sunitinib / Generic mfg.
Enrollment closed, Trial primary completion date, Stroma, Metastases: CYCLIGIST: Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (clinicaltrials.gov) - Oct 2, 2017 P2, N=63, Active, not recruiting, N=10000 --> 20000 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Apr 2018
- |||||||||| Bavencio (avelumab) / EMD Serono, Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment open, Surgery, Metastases: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 2, 2017 P1/2, N=28, Recruiting, Initiation date: Mar 2017 --> Oct 2017 Not yet recruiting --> Recruiting
- |||||||||| Journal: ETV1-positive cells give rise to BRAFV600E mutant gastrointestinal stromal tumors. (Pubmed Central) - Oct 1, 2017
This mouse model of sporadic GIST model was amenable to therapeutic intervention and it recapitulated clinical responses to RAF inhibition seen in human GIST. Our work offers a useful in vivo model of human sporadic forms of BRAF-mutant GIST to help unravel its pathogenesis and therapeutic response to novel experimental agents.
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Review, Journal: Olaratumab for the treatment of advanced soft tissue sarcoma. (Pubmed Central) - Sep 30, 2017 We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. Expert commentary: Olaratumab is a well-tolerated drug that, when combined with doxorubicin, has shown an improved overall survival compared to doxorubicin alone and the phase III confirmatory study is eagerly awaited.
- |||||||||| Review, Journal: Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. (Pubmed Central) - Sep 29, 2017
Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Multi-drug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. (Pubmed Central) - Sep 29, 2017 CIVO also classified patient-specific tumor resistance to the most effective agent, doxorubicin, and further enabled assessment of a preclinical autophagy inhibitor, PS-1001, to reverse doxorubicin resistance...The ability to evaluate and cross-compare multiple drugs and drug combinations simultaneously in living tumors and across a diverse immune-competent patient population may provide a foundation from which to make informed drug development decisions. This method also represents a viable functional approach to complement current precision oncology strategies.
- |||||||||| Enrollment change, Trial initiation date, Trial termination: Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 29, 2017
P2, N=14, Terminated, The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma. N=40 --> 14 | Initiation date: Aug 1998 --> Jun 1996 | Active, not recruiting --> Terminated; slow accrual
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date: Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) (clinicaltrials.gov) - Sep 28, 2017 P2, N=20, Not yet recruiting, Trial primary completion date: Apr 2018 --> Oct 2017 Initiation date: Sep 2017 --> Dec 2017
|